Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2014 / Article
Special Issue

Bioactives and Traditional Herbal Medicine for the Treatment of Cardiovascular/Cerebrovascular Diseases

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 639548 | https://doi.org/10.1155/2014/639548

Dong-Seon Kim, Hyun Dong Ji, Man Hee Rhee, Yoon-Young Sung, Won-Kyung Yang, Seung Hyung Kim, Ho-Kyoung Kim, "Antiplatelet Activity of Morus alba Leaves Extract, Mediated via Inhibiting Granule Secretion and Blocking the Phosphorylation of Extracellular-Signal-Regulated Kinase and Akt", Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 639548, 11 pages, 2014. https://doi.org/10.1155/2014/639548

Antiplatelet Activity of Morus alba Leaves Extract, Mediated via Inhibiting Granule Secretion and Blocking the Phosphorylation of Extracellular-Signal-Regulated Kinase and Akt

Academic Editor: Joen-Rong Sheu
Received23 Sep 2013
Revised21 Dec 2013
Accepted30 Dec 2013
Published19 Feb 2014


Ethnopharmacological Relevance. Morus alba L. leaves (MAE) have been used in fork medicine for the treatment of beriberi, edema, diabetes, hypertension, and atherosclerosis. However, underlying mechanism of MAE on cardiovascular protection remains to be elucidated. Therefore, we investigated whether MAE affect platelet aggregation and thrombosis. Materials and Methods. The anti-platelet activity of MAE was studied using rat platelets. The extent of anti-platelet activity of MAE was assayed in collagen-induced platelet aggregation. ATP and serotonin release was carried out. The activation of integrin αIIbβ3 and phosphorylation of signaling molecules, including MAPK and Akt, were investigated with cytofluorometer and immunoblotting, respectively. The thrombus formation in vivo was also evaluated in arteriovenous shunt model of rats. Results. HPLC chromatographic analysis revealed that MAE contained rutin and isoquercetin. MAE dose-dependently inhibited collagen-induced platelet aggregation. MAE also attenuated serotonin secretion and thromboxane A2 formation. In addition, the extract in vivo activity showed that MAE at 100, 200, and 400 mg/kg significantly and dose-dependently attenuated thrombus formation in rat arterio-venous shunt model by 52.3% (), 28.3% (), and 19.1% (), respectively. Conclusions. MAE inhibit platelet activation, TXB2 formation, serotonin secretion, aggregation, and thrombus formation. The plant extract could be considered as a candidate to anti-platelet and antithrombotic agent.

1. Introduction

Cardiovascular diseases, including thrombosis, stroke, ischemic, and coronary heart diseases, are a leading cause of mortality, accounting for around 30% of global deaths [1]. Especially, thrombotic diseases constitute a major cardiovascular complication affecting a great number of patients. Thrombosis is closely related to activated platelet adhesion, aggregation, secretion functions, and activation of intrinsic and extrinsic coagulation systems, which cause blood coagulation and fibrin formation [2]. Most acute coronary syndromes are caused by platelet aggregation and subsequent thrombus formation in areas of ruptured atheromatous plaques [3, 4]. Therefore, inhibiting platelet function represents a promising approach for preventing thrombosis [5, 6].

Antiplatelet drugs have been developed to inhibit platelet activity in acute thrombotic situations as well as to prevent adverse events and treatment of atherothrombotic disease [7]. Aspirin and clopidogrel for oral administration and glycoprotein IIa/IIIb antagonists (abciximab, eptifibatide, tirofiban, etc.) for injection are commonly used antiplatelet drugs, but they have several clinical disadvantages including gastrointestinal side-effects, hemorrhage and thrombocytopenia [711]. With this regards, much attention has been given to the development of dietary supplements or herbal medicines for prevention or treatment of cardiovascular diseases for their merits in safety [12].

Morus alba L. (Mulberry) leaf belongs to the Moraceae family, distributed mainly in the temperate and subtropical regions in the northern hemisphere. It has been traditionally used in China, Korea, Japan, and other Asian countries as herbal tea as well as herbal medicine. According to the oldest Korean medical book (Dong-ui-bo-gam), it is called “Sang-Yeop” and introduced to be beneficial in alleviating beriberi, edema and pains [13].

Recent studies have reported that it shows antiatherosclerosis [14], antihypertension [15, 16], antiobesity [17], antidiabetic [18, 19], liver protection [20], antiviral [21] and antimicrobial [22] effects. This antiplatelet or antithrombotic effect of M. alba leaves has never been described before, though an antiplatelet effect has been described with its barks [23].

In this study, we discovered that the M. alba leaves extract has strong inhibitory activities on collagen-induced platelet aggregation in vitro and on thrombosis in vivo.

2. Materials and Methods

2.1. Materials

Collagen was obtained from Chrono-Log Co. (Havertown, PA, USA). Aspirin, fibrinogen, plasmin and dimethyl sulfoxide (DMSO) were from Sigma Chemical Co. (St. Louis, MO, USA). Fura-2/AM was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Antibodies against phospho-p44/42, p44/42, phospho-p38, p38, phospho-SAPK/JNK, phospho-PI3K (p85), phospho-Akt, and β-actin were acquired from Cell Signaling (Beverly, MA, USA). ATP assay kits were purchased from Biomedical Research Service Center (Buffalo, NY, USA). A TXB2 enzyme immunoassay (EIA) kit was from Cayman Chemical (Ann Arbor, MI, USA). Fibrinogen Alexa Fluor 488 conjugate was obtained from Molecular Probes (Eugene, OR, USA). HPLC-grade reagents, methanol and water were obtained from J. T. Baker (Phillipsburg, NJ, USA). All other chemicals were of reagent grade.

2.2. Preparation of the Ethanol Extract and Solvent Fractions from Morus alba

Morus alba leaves as a dried herb was purchased from Omniherb Co. (Yeongcheon, Korea) and was authenticated, based on its microscopic and macroscopic characteristics, by the Classification and Identification Committee of the Korea Institute of Oriental Medicine (KIOM). The committee consisted of nine experts in the fields of plant taxonomy, botany, pharmacognosy, and herbology. A voucher specimen (MAL-20120605) was deposited at the herbarium of the Department of Herbal Resources Research at the KIOM.

Dried leaves of Morus alba (500 g) were extracted twice with 70% (v/v) ethanol (5 L) for 4 h under mantle-reflux. The extracts were filtered and evaporated under reduced pressure to give Morus alba leaves extract (MAE, 56.0 g). The extract (40 g) was suspended in water (1.2 L) to be partitioned subsequently with n-hexane (2 × 1.2 L), ethyl acetate (2 × 1.2 L), and then n-butanol (2 × 1.2 L) and the solvent-soluble fractions were evaporated to afford hexane- (3.9 g), ethyl acetate- (1.8 g), butanol- (6.7 g) and water-soluble (27.6 g) fraction, respectively.

The extract and the fractions were dissolved in saline or phosphate-buffered saline (PBS) and then filtered through a 0.22 m syringe filter for experiments.

2.3. High Performance Liquid Chromatography Analysis

The sample was analyzed by reverse phase-high performance liquid chromatography using Waters Alliance 2695 system (Waters Co., Milford, MA, USA), coupled with a 2996 photodiode array detector. Data processing was carried out using Empower software (Waters Co.). Phenomenex Luna C18 column (250 mm × 4.6 mm; particle size 5 μm, Phenomenex, Torrance, CA, USA) was used as stationary phase. The mobile phase consisted of eluent A (0.1% trifluoroacetic in water) and eluent B (acetonitrile). The starting eluent was 90% A and 10% B. The proportion of eluent B was increased linearly to 40% from 10 min to 40 min. The column temperature was kept at 40°C and the detector wavelength was set over the range of 190 to 400 nm and recorded at 360 nm. The flow rate was 1.0 mL/min, and the injection volume was 10 μL, and the column temperature was kept at 40°C.

Identification was based on retention time, UV spectra by comparison with commercial standards. For each compound, peak areas were determined at the wavelength providing maximal UV absorbance. Calibration curves of the standards ranging from 12.5 to 200 μg/mL (5 levels) revealed good linearity with values exceeding 0.99 (peak areas versus concentration). Quantitation was performed based on external standards with a mixture of standards of known concentration that were analyzed in duplicate before and after the batch of samples, and the peak areas were used to calculate the sample contents of the compounds.

2.4. Experimental Animals

Male Sprague Dawley rats (300~350 g) were purchased from Japan SLC (Hamamatsu, Japan). The animals were acclimated for 1 week prior to the experiments, and housed in an air-conditioned animal room with a 12/12 h light/dark cycle at a temperature of °C and humidity of %. The animals were provided with a laboratory diet and water ad libitum.

All experimental protocols involving the use of animals were conducted in accordance with National Institutes of Health (NIH) guidelines and approved by the Committee on Animal Care at the Korea Institute of Oriental Medicine.

2.5. Washed Rat Platelet Preparation

Blood was withdrawn from abdominal vein of rats and collected directly into anticoagulant citrate dextrose (ACD) solution that contained 0.8% citric acid, 2.2% trisodium citrate, and 2% dextrose (w/v). Washed platelets were prepared as previously described [24]. Briefly, platelet-rich plasma (PRP) was obtained by centrifuging rabbit blood samples at 230 ×g for 10 min. Platelets were precipitated by centrifugation of the PRP at 800 ×g for 15 min and washed with HEPES buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM glucose, 3.8 mM HEPES, and pH 6.5) containing 0.35% BSA and 0.4 mM EGTA. The washed platelets were resuspended in HEPES buffer (pH 7.4) and the cell dilution was adjusted to 4 × 108 cells/mL.

2.6. Platelet Aggregation In Vitro Assay

Platelet aggregation was evaluated as previously described [25]. Aggregation was monitored by measuring light transmission with an aggregometer (Chrono-Log, Havertown, PA, USA). The washed platelets (/mL) were pre-incubated at 37°C for 2 min with either MAE or vehicle and then stimulated with 2.5 μg/mL collagen. The mixture was further incubated for 5 min with stirring at 170 ×g. The vehicle concentration was less than 0.1% to minimize the effect of this reagent.

2.7. Measurement

The intracellular calcium ion concentration was measured with Fura-2/AM as previously described [26]. Briefly, the platelets were incubated with 5 μM of Fura-2/AM for 30 min at 37°C and washed. The Fura-2-loaded platelets (3 × 108/mL) were then pre-incubated with MAE for 2 min at 37°C in the presence of 1 mM CaCl2 and subsequently stimulated with collagen for 5 min. Fluorescent signals were recorded using a Hitachi F-2500 fluorescence spectrofluorometer (F-2500, Hitachi, Japan). Light emission was measured at 510 nm with simultaneous excitation at 340 and 380 nm that changed every 0.5 s. Fura-2 fluorescence in the cytosol measured with the spectrofluorometer was calculated as previously described by Schaeffer and Blaustein [27] with the following formula: 224 nM ×  , in which 224 nM is the dissociation constant of the Fura-2-Ca2+ complex, and and represent the fluorescence intensity levels at very low and very high Ca2+ concentrations, respectively. In our experiment, was the intensity of the Fura-2-Ca2+ complex fluorescence at 510 nm after the platelet suspension containing 1 mM of CaCl2 had been solubilized with Triton X-100 (0.1%). was the fluorescence intensity of the Fura-2-Ca2+ complex at 510 nm after the platelet suspension containing 20 mM Tris/3 mM of EGTA had been solubilized with Triton X-100 (0.1%). represented the intensity of Fura-2 complex fluorescence at 510 nm after the platelet suspension was stimulated with collagen with or without MAE in the presence of 1 mM CaCl2.

2.8. ATP Release Assay

Washed platelets (3 × 108/mL) were pre-incubated for 2 min at 37°C with various concentrations of MAE and then stimulated with 2.5 μg/mL collagen. After the reaction was terminated, the cells were centrifuged and the supernatants were used for the assay. ATP release was measured in a luminometer (GloMax 20/20; Promega, Madison, USA) using an ATP assay kit (Biomedical Research Service Center, Buffalo, NY, USA) according to manufacturer’s instructions.

2.9. Measurement of Serotonin Secretion

The washed platelets (/mL) were pre-incubated for 2 min at 37°C with various concentrations of MAE in the presence of 1 mM of Ca2+. The reaction mixture was further incubated with collagen (2.5 μg/mL) for 5 min. After terminating the aggregation reaction, the mixture was immediately centrifuged at 12,000 g for 5 min at 4°C. The supernatant was collected and serotonin release was measured with a serotonin ELISA kit (Labor Diagnostika Nord GmbH & Co, Nordhorn, Germany) according to the manufacturer’s instructions.

2.10. Measurement of Thromboxane Formation

Washed platelets (3 × 108/mL) were pre-incubated with or without MAE for 2 min at 37°C in the presence of 1 mM CaCl2 and then stimulated with 2.5 μg/mL collagen for 5 min. The reactions were terminated by adding ice-cold 2.5 mM EDTA and 100 μM indomethacin. After centrifugation at 12,000 ×g for 3 min at 4°C, the supernatant was collected and the concentration of TXB2 was measured using a TXB2 EIA kit according to the manufacturer’s protocol.

2.11. Immunoblotting

Platelet suspensions (3 × 108/mL) were pre-incubated with MAE or vehicle (0.1% (v/v) DMSO) at 37°C for 2 min. Platelet activation was induced by the addition of 2.5 μg/mL collagen and the reaction was allowed to proceed for 5 min. After terminating the reaction, lysates were then prepared by solubilizing and centrifuging the platelets in sample buffer (0.125 M Tris-HCl, pH 6.8; 2% SDS, 2% β-mercaptoethanol, 20% glycerol, 0.02% bromophenol blue, 1 μg/mL phenylmethylsulfonyl fluoride (PMSF), 2 μg/mL aprotinin, 1 μg/mL leupeptin, and 1 μg/mL pepstatin A). Protein concentration was determined using a BCA assay (PRO-MEASURE; iNtRON Biotechnology, Seoul, Republic of Korea). Total cell proteins (30 μg) from the platelet lysate were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes in transfer buffer (25 mM Tris, pH 8.5; 0.2 M glycine, and 20% methanol). The membranes were blocked in TBS-T containing 5% nonfat dry milk and incubated with primary antibody diluted in a blocking solution. The blots were then incubated with horseradish peroxidase-conjugated secondary antibody. Antibody binding was visualized using enhanced chemiluminescence (iNtRON Biotechnology, Seoul, Republic of Korea).

2.12. Assessment of Fibrinogen Binding to Integrin

Fibrinogen Alexa Fluor 488 conjugate binding to washed platelets was quantified by flow cytometry. Briefly, washed platelets (3 × 108/mL) were pre-incubated for 2 min with various concentrations of MAE at room temperature in the presence of 0.1 mM CaCl2. The platelets were then stimulated with collagen for 5 min, immediately incubated thereafter with fibrinogen Alexa Fluor 488 (20 μg/mL) for 5 min, and finally fixed with 0.5% paraformaldehyde at 4°C for 30 min. The platelets were pelleted by centrifugation at 2,000 ×g at 4°C and resuspended in 500 μL PBS. Since the activation of integrin is largely dependent on the generation of Ca2+, nonspecific binding of fibrinogen to integrin was measured by assessing fibrinogen binding in the presence of the calcium chelator EGTA (1 mM). The fluorescence of each platelet sample was analyzed using a FACS Calibur cytometer (BD Biosciences, San Jose, CA, USA), and data were analyzed using CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).

2.13. MAE Effect on Thrombus Formation in Arteriovenous Shunt Thrombosis Model In Vivo

The in vivo antithrombotic activity of MAE was evaluated in a rat arterio-venous shunt thrombosis model [28]. Rats were given orally administered 400 mg/kg, 200 mg/kg, and 100 mg/kg MAE which were dissolved in 0.25% carboxymethylcellulose (CMC, Sigma, USA) solution at the same time of day for 3 consecutive days by gavage. The shunt thrombosis model was tested 2 h after the last administration. For each test, different batches of six rats were used. After anaesthesia with Urethane (1.25 g/kg i.p) (Sigma, USA), an 8 cm polyethylene tube was inserted between the left jugular vein and the right carotid artery. The saline-filled shunt was assembled by connecting two cannulae with a slightly curved 6 cm long tygon tubing (internal diameter 2 mm) containing a 5 cm long cotton thread (diameter 0.25 mm) which had been scraped with a scalpel blade to render it more thrombogenic. The extracorporeal circulation was maintained for 15 min, during which time a thrombus adheres to the cotton thread. The shunt was then removed and the thread with its associated thrombus was withdrawn and immediately weighed. The thrombus wet weight was determined by subtracting from the value obtained the weight of the dry 5 cm cotton thread determined previously.

2.14. Statistics

Data were analyzed with a one-way analysis of variance followed by a post hoc Dunnett’s test in order to measure statistical significance of the differences observed (SAS Institute Inc., Cary, NC, USA). All data are presented as the mean ± standard error of the mean (SEM). values of 0.05 or less were considered to be statistically significant.

3. Results

3.1. Chromatographic Separation of M. alba Extract

As shown Figure 1, high performance liquid chromatographic (HPLC) analysis of MAE revealed rutin and isoquercetin. The MAE contained  mg/g for rutin and  mg/g for isoquercetin, identified at a retention time of approximately 23.8 min and 24.7 min, respectively.

3.2. Inhibitory Effect of MAE on Collagen-Induced Platelet Aggregation

In the beginning of those studies, we have evaluated whether MAE affected various ligands (ADP-, collagen- and thrombin) induced platelet aggregation. As shown in Figure 2(a), MAE only inhibited collagen-induced platelet aggregation but not in ADP- and thrombin-induced platelet aggregation. In the previous studies [29], we have found that 2.5 μg/mL of collagen, 10 μM of ADP, and 0.1 U/mL of thrombin induced full activation and aggregation of rat platelet. Therefore, we have employed collagen (2.5 μg/mL) as a ligand to induce platelet aggregation in following studies. Figure 2 shows that MAE inhibited collagen- (2.5 μg/mL) induced platelet aggregation in concentration-dependent manner.

3.3. Effect of MAE on Intracellular Calcium Ion Concentration

It is well known that intracellular calcium ion takes a pivotal role in the activation of downstream signaling molecules in platelet aggregation induced by a ligand such as collagen. Therefore, we have investigated whether MAE affect the mobilization induced by 2.5 μg/mL collagen. Collagen induced the massive amount of calcium mobilization by up to  nM, which was significantly and concentration-dependently inhibited by MAE (Figure 3).

3.4. Effects of MAE on the Granule Release

In the following studies, we have examined whether the extract modulated the secretion of granule contents such as ATP and serotonin which can activate platelets themselves acting as autacoids. Collagen (2.5 μg/mL) considerably induced ATP release from dense granule by 3-fold in comparison with resting platelets. As depicted in Figure 4(a), MAE dose-dependently repressed collagen- (2.5 μg/mL) induced ATP release. In order to confirm the MAE’s effect on dense granule, we have chosen another marker molecule serotonin in dense contents. As expected, MAE potently and concentration-dependently inhibited serotonin release which was induced by 2.5 μg/mL collagen (Figure 4(b)).

3.5. Effects of MAE on TXA2 Formation

We next investigated whether MAE affected TXA2 formation in collagen-activated platelets. TXA2 is another marker molecule in the initial activation of ligand binding to cognate receptor. In addition, it acts as an agonist against platelet own receptor, which, therefore, is named “autocoid.” TXB2 is stable metabolite of TXA2 and thus TXB2 formation was measured. Figure 5 displayed that MAE significantly inhibited TXA2 formation in collagen-activated platelets.

3.6. Effects of MAE on the Phosphorylation of MAPKs and Akt

We next investigated whether MAE affected the phosphorylation of mitogen-activated protein kinase (MAPK), including extracellular-signal regulated kinase 1/2 (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK). In previous studies [26, 30], we have shown that all these MAPKs were expressed and phosphorylated by ligands such as ADP and collagen. Our immunoblot analysis revealed that MAE potently inhibited collagen-induced ERK phosphorylation but marginally repressed collagen-induced JNK phosphorylation (Figure 7). However, collagen-induced p38 MAPK phosphorylation was not affected by the extract treatment. In addition, ligand binding to cognate receptor has been shown to activate phosphatidylinositol 3-kinase (PI3K) and Akt, which target the glycogen synthase kinase (GSK) 3 as an Akt effecter. Therefore, we have investigated whether MAE modulated collagen-induced Akt activation. As depicted in Figure 7(b), MAE potently and concentration-dependently suppressed Akt phosphorylation which was activated by collagen.

3.7. Effects of MAE on the Integrin Activation

In order to complete platelet aggregation stably, outside-in signaling pathway should be activated, as determined with fibrinogen binding to active integrin .

The influence of MAE on integrin activation was studied in collagen-stimulated platelets. As shown in Figure 6, collagen (2.5 μg/mL) increased the fibrinogen binding to active integrin , whereas resting platelets did not activate the integrin.

The plant extracts reduced collagen- (2.5 μg/mL) induced fibrinogen binding to integrin in concentration-dependent manner (Figure 6).

3.8. Effect of MAE on Arteriovenous Shunt Thrombosis

The AV-shunt thrombosis model has been commonly used to assess antithrombotic effects. Compared to the control, a 3-day oral treatment with MAE decreased thrombus weight in the rat arteriovenous shunt thrombosis model. As shown in Figure 8, after oral administration of 100, 200, and 400 mg/kg/day, MAE significantly and dose-dependently decreased the thrombus weight by 52.3% (), 28.3% (), and 19.1% () compared to vehicle control, respectively. Rivaroxaban which was used as a positive control is an oral anticoagulant for the prevention and treatment of thrombosis mediated conditions [31]. Rivaroxaban 5 mg/kg/day was different from control () and MAE 100 mg/kg/day (), but not from MAE 200 mg/kg/day and 400 mg/kg/day.

4. Discussion

These results show that in vitro the ethanol extract of M. alba L. leaf (MAE) inhibits collagen-induced platelet aggregation in a concentration-dependent manner. In order to elucidate the mechanism of inhibitory activities of MAE extract, we have analyzed downstream signaling as follows intracellular calcium concentration, dense granule secretions, protein phosphorylations (e.g., MAPKs and Akt), and integrin signaling. In addition, we next investigated whether this efficacy of MAE in vitro is implemented in in vivo application. That is, the extract given orally to rats for 3 days dose-dependently decreased thrombus weight in a common model of arterial thrombosis. To the best of our knowledge this is the first report to demonstrate the effects on platelet aggregation and thrombosis.

Upon the ligand binding to platelet membrane receptors, plays an important role in the initial activation of platelet and subsequent platelet aggregation. Upregulation of is due to both calcium influx from extracellular fluid and calcium mobilization from intracellular pools, such as dense tubular system and mitochondria. Although unknown is the source of , collagen dramatically escalates intracellular calcium concentration which is significantly and concentration-dependently reduced by MAE. In addition, we did not determined whether MAE modulate either calcium influx in platelet membrane or inositol-1,4,5-trisphosphate (IP3) receptor on platelet organelles. However, MAE potently blocked collagen-induced upregulation which is at least main cause of antiplatelet activity.

Mammalian platelets devoid of nucleus and basically transcriptional and translational activities are limited. Although platelet transcription factors such as nuclear factor kappa B (NF-B) are some reported [32, 33], it is largely understood that new functional protein synthesis is limited. Therefore, granule substances take a pivotal role in the platelet activation and aggregation due to its biological and functional significance. For example, dense granules enclosed ATP, ADP, serotonin and Ca2+. They act as an autacoid (e.g., self-activator) or an important modulator in the downstream signaling. Therefore, the MAE’s antiplatelet activity might be due to the potent inhibition of granule secretion (i.e., Ca2+, ATP, and serotonin) (Figure 9).

The activation of integrin is plays an important role in the final step of platelet activation and aggregation, which is named as inside-out signaling. That is, the phosphorylation of integrin is able to bind to another phosphorylated integrin , which is mediated via fibrinogen-like bridge network. Finally, strict and stable blood thrombus is being formed. Therefore, screening of pharmacological inhibitors is widely being investigated for antiplatelet and antithrombotic agents. At the moment, we insisted that MAE could be developed as antiplatelet or antithrombotic agents or functional food.

On the other hand, the phosphorylation of signaling molecules, including MAPKs (i.e., ERK1/2, p38 MAPK, and JNK) and PI3K/Akt is also crucial phase in outside-in and inside-out signaling of platelet aggregation. In our results, the collagen-induced phosphorylation of ERK and JNK was inhibited by MAE but not p38 MAPK. Although the role of ERK and JNK in platelet physiology is not clear, there are several evidences that they are involved in the activation of integrin and PLA2/TXA2 pathways [34, 35]. In addition, MAE blocked collagen-induced TXA2 production (Figure 5). This indicated that MAE blocked MAPK-integrin and PLA2/TXA2 routs and thus displayed potent antiplatelet activity.

On the other hand, PI3-K/Akt pathway plays important role in the platelet activation and aggregation. The receptor activation leads to the phosphorylation of PI3-K and subsequently activation and phosphorylation of Akt. Moreover, it is reported that signaling routes of PI3-K are involved in the transient activation of integrin . As shown in Figure 7(b), MAE significantly inhibited both PI3-K and Akt phosphorylation. However, at the moment, direct inhibition of MAE on either PI3-K or PI3-K and Akt is not clear, which remains to be elucidated in the future.

Blood flow disturbances at sites of atherosclerotic plaque rupture promote platelet activation and arterial thrombus formation [36, 37]. In the present study, MAE significantly inhibited collagen-induced platelet aggregation in vitro and rat carotid artery thrombus formation in vivo. Therefore, MAE has potential to prevent thrombotic or cardiovascular disease.

MAE also inhibited serotonin and ATP secretion in a concentration-dependent manner. Serotonin and ATP can cause vasoconstriction of interarterial coronary collateral vessels, and they suggest that platelet activation in coronary arteries that are linked to collateral vessels has the potential to cause collateral vasoconstriction, thereby compromising blood flow to the dependent myocardium [3840]. Therefore MAE might be used for prevention or treatment of myocardial infarction.

The butanol-soluble fraction from MAE showed the strongest inhibitory effect against collagen-induced platelet aggregation when compared with other fractions, hexane, ethyl acetate and water fractions of MAE. The finding indicates that active principles are medium polar, suggesting that alcoholic extract rather than water extract such as tea or beverage might be beneficial for cardiovascular.

In this study, from MAE we identified two quercetin glycosides, rutin and isoquercetin, which have been reported to be major components of M. alba leaf along with quercetin as major components in M. alba leaf [18, 41].

We also further evaluated the inhibitory effects of rutin and isoquercetin at high concentration of 400 μg/mL on collagen-induced platelet aggregation, but they slightly inhibited (Data not shown). Since their aglycone, quercetin, is known to inhibit strongly on platelet aggregation rabbit platelets induced by collagen, ADP, or arachidonic acid [26, 42], we also investigated its existence using its commercial standard but not identified on HPLC chromatogram; a standard quercetin was retained approximately at 34.6 min (data not shown), but any traceable peak was not appeared near the retention time as shown Figure 1. Further study would be required in order to identify the active compound(s).

5. Conclusions

In in vitro assays using freshly isolated rat platelets, the MAE showed significant inhibition of collagen-induced platelet aggregation, and these effects were also associated with reduced , ATP and serotonin secretion, and integrin . In accordance with these enhanced in vitro antiplatelet activities, the extract showed enhanced antithrombotic effects in in vivo arterial thrombosis model. Thus, these results suggest that MAE can be a good candidate to an antiplatelet and antithrombotic agent.

Conflict of Interests

The authors declare that they have no conflict of interests.


This work was mainly supported by Discovery of Herbal Medicine for Prevention (K13202), the Korea Institute of Oriental Medicine (KIOM) to the Ministry of Science, ICT & Future Planning (MSIP), Korea. Additionally, this work was also partially supported by ICT Fusional Construction of Alternative Herbal Medicine Resources (K14410), Characterization of Native Biological Resources and Excavation of Alternative Herbal Medicine Resources (K14411), the Korea Institute of Oriental Medicine (KIOM) to the Ministry of Science, ICT & Future Planning (MSIP), Korea.


  1. L. H. Lindholm and S. Mendis, “Prevention of cardiovascular disease in developing countries,” The Lancet, vol. 370, no. 9589, pp. 720–722, 2007. View at: Publisher Site | Google Scholar
  2. A. Stoyioglou and M. R. Jaff, “Medical treatment of peripheral arterial disease: a comprehensive review,” Journal of Vascular and Interventional Radiology, vol. 15, no. 11, pp. 1197–1207, 2004. View at: Publisher Site | Google Scholar
  3. E. Falk, “Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi,” British Heart Journal, vol. 50, no. 2, pp. 127–134, 1983. View at: Google Scholar
  4. J. T. Willerson, P. Golino, J. Eidt, W. B. Campbell, and L. M. Buja, “Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications,” Circulation, vol. 80, no. 1, pp. 198–205, 1989. View at: Google Scholar
  5. C. J. Pepine, “Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care,” Annals of Medicine, vol. 42, no. 1, pp. 19–35, 2010. View at: Publisher Site | Google Scholar
  6. D. Varon and G. Spectre, “Antiplatelet agents,” Hematology, pp. 267–272, 2009. View at: Google Scholar
  7. C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth, “Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, no. 3, supplement, pp. 234S–264S, 2004. View at: Google Scholar
  8. D. L. Bhatt and E. J. Topol, “Scientific and therapeutic advances in antiplatelet therapy,” Nature Reviews Drug Discovery, vol. 2, no. 1, pp. 15–28, 2003. View at: Publisher Site | Google Scholar
  9. W. G. Eisert, “How to get from antiplatelet to antithrombotic treatment,” American Journal of Therapeutics, vol. 8, no. 6, pp. 443–449, 2001. View at: Google Scholar
  10. P. A. Gum, K. Kottke-Marchant, P. A. Welsh, J. White, and E. J. Topol, “A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease,” Journal of the American College of Cardiology, vol. 41, no. 6, pp. 961–965, 2003. View at: Publisher Site | Google Scholar
  11. S. H. Rezkalla and M. Benz, “Antiplatelet therapy from clinical trials to clinical practice,” Clinical Medicine & Research, vol. 1, no. 2, pp. 101–104, 2003. View at: Google Scholar
  12. J. Heo, Dongeuibogam, Bubin Publishers, Seoul, South Korea, 2012.
  13. F. B. Hu, “Plant-based foods and prevention of cardiovascular disease: an overview,” The American Journal of Clinical Nutrition, vol. 78, no. 3, supplement, pp. 544S–551S, 2003. View at: Google Scholar
  14. M.-Y. Yang, C.-N. Huang, K.-C. Chan, Y.-S. Yang, C.-H. Peng, and C.-J. Wang, “Mulberry leaf polyphenols possess antiatherogenesis effect via inhibiting LDL oxidation and foam cell formation,” Journal of Agricultural and Food Chemistry, vol. 59, no. 5, pp. 1985–1995, 2011. View at: Publisher Site | Google Scholar
  15. J. Naowaboot, P. Pannangpetch, V. Kukongviriyapan, U. Kukongviriyapan, S. Nakmareong, and A. Itharat, “Mulberry leaf extract restores arterial pressure in streptozotocin-induced chronic diabetic rats,” Nutrition Research, vol. 29, no. 8, pp. 602–608, 2009. View at: Publisher Site | Google Scholar
  16. N.-C. Yang, K.-Y. Jhou, and C.-Y. Tseng, “Antihypertensive effect of mulberry leaf aqueous extract containing γ-aminobutyric acid in spontaneously hypertensive rats,” Food Chemistry, vol. 132, no. 4, pp. 1796–1801, 2012. View at: Publisher Site | Google Scholar
  17. K.-S. Oh, S. Y. Ryu, S. Lee et al., “Melanin-concentrating hormone-1 receptor antagonism and anti-obesity effects of ethanolic extract from Morus alba leaves in diet-induced obese mice,” Journal of Ethnopharmacology, vol. 122, no. 2, pp. 216–220, 2009. View at: Publisher Site | Google Scholar
  18. T. Katsube, M. Yamasaki, K. Shiwaku et al., “Effect of flavonol glycoside in mulberry (Morus alba L.) leaf on glucose metabolism and oxidative stress in liver in diet-induced obese mice,” Journal of the Science of Food and Agriculture, vol. 90, no. 14, pp. 2386–2392, 2010. View at: Publisher Site | Google Scholar
  19. J. M. Park, H. Y. Bong, H. I. Jeong, Y. K. Kim, J. Y. Kim, and O. Kwon, “Postprandial hypoglycemic effect of mulberry leaf in Goto-Kakizaki rats and counterpart control Wistar rats,” Nutrition Research and Practice, vol. 3, no. 4, pp. 272–278, 2009. View at: Google Scholar
  20. L. S. Hsu, H. H. Ho, M. C. Lin, C. C. Chyau, J. S. Peng, and C. J. Wang, “Mulberry water extracts (MWEs) ameliorated carbon tetrachloride-induced liver damages in rat,” FFood and Chemical Toxicology, vol. 50, no. 9, pp. 3086–3093, 2012. View at: Google Scholar
  21. J. Du, Z.-D. He, R.-W. Jiang, W.-C. Ye, H.-X. Xu, and P. P.-H. But, “Antiviral flavonoids from the root bark of Morus alba L,” Phytochemistry, vol. 62, no. 8, pp. 1235–1238, 2003. View at: Publisher Site | Google Scholar
  22. W. Wang, Y. Zu, Y. Fu, and T. Efferth, “In vitro antioxidant and antimicrobial activity of extracts from Morus alba L. leaves, stems and fruits,” American Journal of Chinese Medicine, vol. 40, no. 2, pp. 349–356, 2012. View at: Publisher Site | Google Scholar
  23. J. J. Lee, H. Yang, Y. M. Yoo et al., “Morusinol extracted from Morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease,” Journal of Atherosclerosis and Thrombosis, vol. 19, no. 6, pp. 516–522, 2012. View at: Google Scholar
  24. D.-H. Lee, H.-J. Cho, H.-Y. Kang, M. H. Rhee, and H.-J. Park, “Total saponin from Korean red ginseng inhibits thromboxane A2 production associated microsomal enzyme activity in platelets,” Journal of Ginseng Research, vol. 36, no. 1, pp. 40–46, 2012. View at: Publisher Site | Google Scholar
  25. J. Y. Park, W. J. Oh, M. J. Kim et al., “Mechanism of anti-platelet activity of Oligoporus tephroleucus oligoporin A: involvement of extracellular signal-regulated kinase phosphorylation and cyclic nucleotide elevation,” Platelets, vol. 23, no. 5, pp. 376–385, 2012. View at: Publisher Site | Google Scholar
  26. W. J. Oh, M. Endale, S. C. Park, J. Y. Cho, and M. H. Rhee, “Dual roles of quercetin in platelets: phosphoinositide-3-kinase and MAP kinases inhibition, and cAMP-dependent vasodilator-stimulated phosphoprotein stimulation,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 485262, 2012. View at: Publisher Site | Google Scholar
  27. J. Schaeffer and M. P. Blaustein, “Platelet free calcium concentrations measured with fura-2 are influenced by the transmembrane sodium gradient,” Cell Calcium, vol. 10, no. 2, pp. 101–113, 1989. View at: Google Scholar
  28. T. Umetsu and K. Sanai, “Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats,” Thrombosis and Haemostasis, vol. 39, no. 1, pp. 74–83, 1978. View at: Google Scholar
  29. S. D. Kim, I.-K. Lee, W. M. Lee et al., “The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase,” European Journal of Pharmacology, vol. 584, no. 2-3, pp. 361–367, 2008. View at: Publisher Site | Google Scholar
  30. J. Y. Park, M. Hong, Q. Jia et al., “Pistacia chinensis methanolic extract attenuated MAPK and akt phosphorylations in ADP stimulated rat platelets In vitro,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 895729, 7 pages, 2012. View at: Publisher Site | Google Scholar
  31. T. C. Sarich, G. Peters, S. D. Berkowitz et al., “Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions,” Annals of the New York Academy of Sciences, vol. 1291, pp. 42–55, 2013. View at: Google Scholar
  32. H.-S. Lee, S. D. Kim, W. M. Lee et al., “A noble function of BAY 11-7082: inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations,” European Journal of Pharmacology, vol. 627, no. 1–3, pp. 85–91, 2010. View at: Publisher Site | Google Scholar
  33. A. Hachem, D. Yacoub, Y. Zaid, W. Mourad, and Y. Merhi, “Involvement of nuclear factor kappaB in platelet CD40 signaling,” Biochemical and Biophysical Research Communications, vol. 425, no. 1, pp. 58–63, 2012. View at: Google Scholar
  34. S. Gambaryan, A. Kobsar, N. Rukoyatkina et al., “Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase a from an NFκB-IκB complex,” Journal of Biological Chemistry, vol. 285, no. 24, pp. 18352–18363, 2010. View at: Publisher Site | Google Scholar
  35. A. Garcia, H. Shankar, S. Murugappan, S. Kim, and S. P. Kunapuli, “Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets,” Biochemical Journal, vol. 404, no. 2, pp. 299–308, 2007. View at: Publisher Site | Google Scholar
  36. Z. Li, X. Xi, and X. Du, “A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin αIIbβ3,” Journal of Biological Chemistry, vol. 276, no. 45, pp. 42226–42232, 2001. View at: Publisher Site | Google Scholar
  37. J. Chou, N. Mackman, G. Merrill-Skoloff, B. Pedersen, B. C. Furie, and B. Furie, “Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation,” Blood, vol. 104, no. 10, pp. 3190–3197, 2004. View at: Publisher Site | Google Scholar
  38. S. R. Steinhubl and D. J. Moliterno, “The role of the platelet in the pathogenesis of atherothrombosis,” American Journal of Cardiovascular Drugs, vol. 5, no. 6, pp. 399–408, 2005. View at: Publisher Site | Google Scholar
  39. L. M. Buja and J. T. Willerson, “Effects of serotonin and thromboxane A2 on the coronary collateral circulation,” Journal of the American College of Cardiology, vol. 19, no. 3, pp. 694–695, 1992. View at: Google Scholar
  40. D. H. Cowan, “Platelet adherence to collagen: role of prostaglandin—thromboxane synthesis,” British Journal of Haematology, vol. 49, no. 3, pp. 425–434, 1981. View at: Google Scholar
  41. P. Golino, L. M. Buja, Y. Sheng-Kun, J. McNatt, and J. T. Willerson, “Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo,” Journal of the American College of Cardiology, vol. 15, no. 3, pp. 718–726, 1990. View at: Google Scholar
  42. G.-N. Kim and H.-D. Jang, “Flavonol content in the water extract of the mulberry (Morus alba L.) leaf and their antioxidant capacities,” Journal of Food Science, vol. 76, no. 6, pp. C869–C873, 2011. View at: Publisher Site | Google Scholar

Copyright © 2014 Dong-Seon Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles